Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus ZERVIATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus ZERVIATE.
PROMETHAZINE DM vs ZERVIATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
ZERVIATE (cetirizine ophthalmic solution) contains cetirizine, a selective histamine H1 receptor antagonist. It inhibits histamine-induced vasodilation and increased vascular permeability, leading to reduction of ocular itching associated with allergic conjunctivitis.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
1 drop in each affected eye twice daily (approximately 8 hours apart).
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Terminal elimination half-life is approximately 3 hours; clinical context: supports twice-daily topical ocular dosing for allergic conjunctivitis.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal excretion of unchanged drug (approximately 70%) and metabolites; biliary/fecal elimination accounts for less than 20%.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine